Objective <p>Effect of levocetirizine hydrochloride dispersible tablets on inflammatory factors in the treatment of chronic urticaria(CU) was examined.</p> Methods <p>100 patients with CU were divided into an observation group (treatment with levocetirizine hydrochloride dispersible tablets) and a control group (conventional treatment).</p> Results <p>The total effective rate and incidence of adverse reactions in the control group were lower than those in the observation group. Following a four-week course of therapy, the observation group’s levels of serotonin (5-HT), interleukin-4 (IL-4), and interleukin-17 (IL-17) were all greater. Both the UAS and DLQI scores were much lower than they were prior to therapy, and the observation group’s scores were considerably lower. The relief time of symptoms such as skin itching, redness, tingling, and fever in the observation group was shorter; suggesting that the therapy of persistent urticaria with dispersible tablets containing levocetirizine hydrochloride is viable.</p> Conclusion <p>When levocetirizine hydrochloride dispersible tablets are used to treat CU, the patient’s inflammatory response is decreased, inflammatory factors 5-HT, IL-4, and IL-17 levels are improved, the associated symptoms are encouraged to resolve, adverse responses are prevented, and a better prognosis is provided.</p>